Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy

• Published in: Cardiovascular therapeutics Vol. 2019; no. 2019; pp. 1 - 10
• Main Authors: Lee, Eunmi, Seo, Hong Seog, Park, Chang G., Kim, Eung Ju, Kim, Jin Won, Choi, Cheol Ung, Na, Jin Oh, Choi, Byoung Geol, Lee, Yuchang, Hyun, Myung Han, Rha, Seung-Woon
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2019; Hindawi; John Wiley & Sons, Inc; Hindawi Limited; Hindawi-Wiley
• Subjects: Age; Aged; Angina pectoris; Angioplasty; Anti-Inflammatory Agents - adverse effects; Anti-Inflammatory Agents - therapeutic use; Apolipoproteins; Atherosclerosis; Atrial fibrillation; Biomarkers - blood; C-reactive protein; C-Reactive Protein - metabolism; Cardiac patients; Cardiology; Cardiovascular disease; Cardiovascular Diseases - blood; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - mortality; Cardiovascular Diseases - prevention & control; Care and treatment; Cholesterol; Cholesterol, LDL - blood; Clinical outcomes; Clinical trials; Clopidogrel; Comparative analysis; Coronary vessels; Diabetes; Disease prevention; Down-Regulation; Dyslipidemias - blood; Dyslipidemias - diagnosis; Dyslipidemias - drug therapy; Dyslipidemias - mortality; Female; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Incidence; Inflammation; Inflammation - blood; Inflammation - diagnosis; Inflammation - drug therapy; Inflammation - mortality; Laboratories; Lipoproteins; Low density lipoproteins; Male; Middle Aged; Mortality; Population; Registries; Risk Assessment; Risk Factors; Statins; Time Factors; Transluminal angioplasty; Treatment Outcome; Trimetazidine
• ISSN: 1755-5914; 1755-5922
• DOI: 10.1155/2019/3824823

In statin therapy, the prognostic role of achieved low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hsCRP) in cardiovascular outcomes has not been fully elucidated. A total of 4,803 percutaneous coronary intervention (PCI)-naïve patients who prescribed moderate intensity of statin therapy were followed up. Total and each component of major adverse cardiovascular events (MACE) according to LDL-C and hsCRP quartiles were compared. The incidence of 5-year total MACEs in the highest quartile group according to the followed-up hsCRP was higher than that in the lowest quartile (hazard ratio (HR) = 2.16, p<0.001). However, there was no difference between the highest and lowest quartiles of the achieved LDL-C (HR = 0.95, p=0.743). After adjustment of potential confounders, the incidence of total death, de novo PCI, atrial fibrillation, and heart failure in the highest quartile of followed-up hsCRP, was higher than that in the lowest quartile (all p<0.05). However, other components except for de novo PCI in the highest quartile by achieved LDL-C was not different to that in the lowest quartile. These results suggest that followed-up hsCRP can be more useful for predicting future cardiovascular outcome than achieved LDL-C in PCI-naïve patients with statin therapy.